Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer

The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-A...

Full description

Bibliographic Details
Main Authors: Ayman Abouzayed, Hanna Tano, Ábel Nagy, Sara S. Rinne, Fadya Wadeea, Sharmishtaa Kumar, Kristina Westerlund, Vladimir Tolmachev, Amelie Eriksson Karlström, Anna Orlova
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Pharmaceutics
Subjects:
prostate cancer
gastrin-releasing peptide receptor
RM26
albumin-binding domain
targeted therapy
gastrin-releasing peptide receptors (GRPR) antagonist
Online Access:https://www.mdpi.com/1999-4923/12/10/977

Similar Items

Similar Items